Relationship of prostaglandin efficacy with race

Article

Ethnicity does not effect treatment, according to Dr Catherine Birt

It has been indicated in prior studies that there is a link between a patient's ethnicity and the efficacy of prostaglandin analogues. In a study performed by Dr P.A. Netland et al. it was reported that travoprost was significantly better than latanoprost or timolol at lowering intraocular pressure (IOP) in black patients.1

"Netland and the Travoprost Study Group had reported that travoprost was more effective than latanoprost in lowering IOP in black patients," said Dr Catherine Birt when discussing her initial reasons for performing her study to examine this possible relationship. "Netland et al. later published a reanalysis of two studies, pooling data to examine the response to travoprost in black and non-black patients. These data showed that travoprost lowered mean IOP further in black patients than in non-black patients by an average of 8.1 mmHg compared to 7.0 mmHg respectively."

Considering the results from previous studies, Dr Birt (Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada) and her team were able to perform a prospective randomized investigator-masked multicentre investigation on the relationship between prostaglandin efficacy and patient race.

The investigatormasked, multicentre comparison involved testing three prostaglandins on 83 patients from 9 different sites with either newly diagnosed openangle glaucoma or elevated IOP after a 'washout' period. Each patient was randomized to receive either latanoprost, travoprost or bimatoprost but assignment was balanced by racial group and study site.

"Ethnicity of the patient was based on a self report system, not DNA or other objective markers," added Dr Birt. "The investigators were masked to the drug assignment of the participants which was made on the basis of a randomization schedule, balanced for ethnicity and drug assignment, produced for each participating site by the biostatistician."

Patients completed follow-ups at 2, 6, 12 and 24 weeks, with local side effects assessed each time.

Surprise results

"All three of the prostaglandin drugs were highly effective at lowering IOP. No differences in effect between the drugs or between members of different racial groups were detected, and no interaction between drug and ethnicity was detected," revealed Dr Birt. "Our null hypothesis stated that there would be no ethnic-based difference in IOP lowering effectiveness, and/or safety profile, between the three medications; the alternative hypothesis was that such a difference existed."

The findings did show a significant IOP decrease from baseline to 12 weeks and from baseline to 24 weeks. No interaction was found between racial group and the prostaglandins used. Dr Birt highlighted. "This was in keeping with the null hypothesis. Based on the Netland results, we had expected to find that travoprost was more effective in the African-derived patients, but this is not the result our data supported."

The surprising results may be due to the fact that the study size sample was smaller than desired. Dr Birt claimed, "Our sample size was smaller than required; with unlimited time and money a larger study could be done; a multicentre study in different areas of the world would also be an interesting way of examining this question, but with significant logistical difficulties."

In conclusion, Dr Birt's investigation showed that all three prostaglandins are equally successful in lowering IOP. Dr Birt said, "By increasing uveoscleral outflow and lowering IOP, prostaglandins are highly effective for relieving pressure in open-angle glaucoma patients."

Dr Catherine Birt is a glaucoma specialist and belongs to the Toronto Area Glaucoma Society, Canada. She can be contacted by E-mail: catherine.birt@sunnybrook.ca

Dr Birt has indicated she is a speaker/consultant to Alcon, Allergan, Merck, and Pfizer.

Reference

1. P.A. Netland et al., Am. J. Ophthalmol., 2001;132(4):472–484.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.